First and foremost is our focus on the strength of our team with both proven scientific and practical experience, forged into one unit by a common commitment to the aims of this Focused Research Organization.

Growth of the members of the Institute over the upcoming periods will be carefully cultivated. Respect and camaraderie are featured elements, along with efficiency and focus. Dialog is vital, both internally as well as in skillful outreach across stakeholder communities.

The work of the Institute for Molecular Intelligence™ develops potent, integrated drug discovery methods tuned for incisive molecular design and molecular transmutation, in a set of blended lab & computational platforms at the heart of our non-profit Institute.

Benefits include the delivery of potential new medicines, by harnessing decades of genomic and chemical knowledge coupled with physics and chemistry-informed 3D AI.

The core pursuit is to empower the fight against Anti-Microbial Resistance, by accelerating a parallel attack on numerous microbiological target pathways at once.

This core focus encompasses ESKAPE pathogens, TB and related mycobacteria, as well as fungal diseases.

Partnerships then extend the beneficial applications of the platform to broader areas of human disease.

Institute for Molecular Intelligence™

Powering AI's Fundamental ability to perceive Chemistry

The power of AI in the design and optimization of new medicines is on the cusp of launching into a new era. 

Medicinal R&D, however, is not to be underestimated as a complex multi-disciplinary challenge. The delivery of new drugs requires the relentless pursuit of a pipeline of Qualified Leads, preclinical IND-ready Drug Candidates, and phase-2-ready Drug Candidates that then feed into the ecosystem of pharma and biotech companies. A new pipeline with these deliverables is enabled by the novel approaches being championed by the Institute for Molecular Intelligence™.

The Institute is being designed with the ability to partner at all stages from fundamental discovery biology to the out-licensing of advanced Drug Candidates discovered internally through the Institute’s core methods.

Affiliates bring deep expertise in specialties ranging from BSL3 studies of pathogenic bacteria, including mycobacteria, and up through sophisticated functional models of disease. The Institute can supply a highly selective pipeline of innovative chemical leads delivered at a scale and quality that matches the throughput of those incisive disease-relevant models.